IMPORTANCE: Use of haploidentical (HAPLO) stem cell transplantation with posttransplant cyclophosphamide is rapidly increasing in adults with hematologic cancers. However, its specific role compared with other transplant strategies has yet to be identified. OBJECTIVE: To synthesize the existing evidence regarding outcomes of stem cell transplantations comparing HAPLO stem cell transplantation and posttransplant cyclophosphamide therapy with transplantations from matched related donors (MRDs), matched unrelated donors (MUDs), or mismatched unrelated donors (MMUDs). DATA SOURCES: PubMed, Cochrane Library, ClinicalTrials.gov, and meeting abstracts were searched for the key words haploidentical and cyclophosphamide from inception through March 1, 2019. STUDY SELECTION: Studies comparing HAPLO stem cell transplantation and posttransplant cyclophosphamide therapy with transplantations from other donors in adults with hematologic cancers were eligible for meta-analysis. DATA EXTRACTION AND SYNTHESIS: Pooled odds ratios (ORs) and 95% CIs were calculated using a random-effects model. MAIN OUTCOMES AND MEASURES: Main outcomes were all-cause mortality, nonrelapse mortality, and relapse. RESULTS: A total of 30 studies including 22 974 participants were analyzed. HAPLO stem cell transplantation with posttransplant cyclophosphamide therapy was associated with increased all-cause mortality compared with MRDs (OR, 1.17; 95% CI, 1.05-1.30), similar all-cause mortality compared with MUDs (OR, 1.06; 95% CI, 0.96-1.18), and reduced all-cause mortality compared with MMUDs (OR, 0.75; 95% CI, 0.61-0.92). Regarding nonrelapse mortality, HAPLO stem cell transplantation with posttransplant cyclophosphamide was associated with worse outcomes compared with MRDs (OR, 1.20; 95% CI, 1.04-1.40) but better outcomes compared with MUDs (OR, 0.75; 95% CI, 0.61-0.92) and MMUDs (OR, 0.51; 95% CI, 0.25-1.02). In terms of relapse, HAPLO stem cell transplantation with posttransplant cyclophosphamide was associated with similar outcome compared with MRDs (OR, 1.01; 95% CI, 0.86-1.17) and MMUDs (OR, 1.06; 95% CI, 0.77-1.47) but showed increased relapse compared with MUDs (OR, 1.20; 95% CI, 1.03-1.40). CONCLUSIONS AND RELEVANCE: Results of this meta-analysis suggest that MRDs, if available, remain the optimal donors regarding mortality and HAPLO stem cell transplantation with posttransplant cyclophosphamide may be preferred over MMUDs. Prospective comparisons with MUDs are needed.

Amsterdam University Medical Center Vrije Universiteit Department of Hematology Cancer Center Amsterdam Amsterdam the Netherlands

Department of Hematology Hospital Universitari i Politècnic La Fe Valencia Spain

Department of Hematology L and A Seràgnoli University of Bologna S Orsola Malpighi Hospital Bologna Italy

Department of Stem Cell Transplantation University Medical Center Hamburg Eppendorf Hamburg Germany

Division of Hematology Basel University Hospital Basel Switzerland

Fondazione Policlinico Universitario A Gemelli Institute of Scientific Research and Treatment Universita' Cattolica del Sacro Cuore Rome Italy

Goethe University Hospital Department of Medicine 2 Hematology Oncology Frankfurt am Main Germany

Hematology and Bone Marrow Transplantation Unit Azienda Ospedaliera Papa Giovanni XXIII Bergamo Italy

Hospital Clinico Universitario INCLIVA Biomedical Research Institute University of Valencia Valencia Spain

Institute for Hematology and Blood Transfusion Hospital Na Bulovce Prague Czech Republic

Turku University Hospital Turku Finland

Komentář v

JAMA Oncol. 2020 May 1;6(5):786-787. doi: 10.1001/jamaoncol.2020.0167. PubMed

Komentář v

JAMA Oncol. 2020 May 1;6(5):787-788. doi: 10.1001/jamaoncol.2020.0173. PubMed

Zobrazit více v PubMed

Passweg JR, Baldomero H, Bader P, et al. . Use of haploidentical stem cell transplantation continues to increase. Bone Marrow Transplant. 2017;52(6):811-817. doi:10.1038/bmt.2017.34 PubMed DOI PMC

Saito AM, Cutler C, Zahrieh D, et al. . Costs of allogeneic hematopoietic cell transplantation with high-dose regimens. Biol Blood Marrow Transplant. 2008;14(2):197-207. doi:10.1016/j.bbmt.2007.10.010 PubMed DOI PMC

Beatty PG, Clift RA, Mickelson EM, et al. . Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med. 1985;313(13):765-771. doi:10.1056/NEJM198509263131301 PubMed DOI

Szydlo R, Goldman JM, Klein JP, et al. . Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol. 1997;15(5):1767-1777. doi:10.1200/JCO.1997.15.5.1767 PubMed DOI

Gratwohl A, Pasquini MC, Aljurf M, et al. ; Worldwide Network for Blood and Marrow Transplantation (WBMT) . One million haemopoietic stem-cell transplants. Lancet Haematol. 2015;2(3):e91-e100. doi:10.1016/S2352-3026(15)00028-9 PubMed DOI

Devine SM. Haploidentical hematopoietic cell transplantation using post-transplantation cyclophosphamide: does graft source matter? J Clin Oncol. 2017;35(26):2984-2986. doi:10.1200/JCO.2017.73.7775 PubMed DOI

Passweg JR, Baldomero H, Basak GW, et al. ; European Society for Blood and Marrow Transplantation (EBMT) . The EBMT activity survey report 2017[published online February 6, 2019]. Bone Marrow Transplant. 2019. doi:10.1038/s41409-019-0465-9 PubMed DOI PMC

O’Donnell PV, Luznik L, Jones RJ, et al. . Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002;8(7):377-386. doi:10.1053/bbmt.2002.v8.pm12171484 PubMed DOI

Luznik L, O’Donnell PV, Symons HJ, et al. . HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641-650. doi:10.1016/j.bbmt.2008.03.005 PubMed DOI PMC

Yang B, Yu R, Cai L, et al. . Haploidentical versus matched donor stem cell transplantation for patients with hematological malignancies. Bone Marrow Transplant. 2019;54(1):99-122. doi:10.1038/s41409-018-0239-9 PubMed DOI

Gu Z, Wang L, Yuan L, et al. . Similar outcomes after haploidentical transplantation with post-transplant cyclophosphamide versus HLA-matched transplantation. Oncotarget. 2017;8(38):63574-63586. doi:10.18632/oncotarget.18862 PubMed DOI PMC

Chen D, Zhou D, Guo D, Xu P, Chen B. Comparison of outcomes in hematological malignancies treated with haploidentical or HLA-identical sibling hematopoietic stem cell transplantation following myeloablative conditioning. PLoS One. 2018;13(1):e0191955. doi:10.1371/journal.pone.0191955 PubMed DOI PMC

Yu X, Liu L, Xie Z, et al. . Bone marrow versus peripheral blood as a graft source for haploidentical donor transplantation in adults using post-transplant cyclophosphamide. Crit Rev Oncol Hematol. 2019;133:120-128. doi:10.1016/j.critrevonc.2018.05.017 PubMed DOI

Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. http://handbook-5-1.cochrane.org/. Updated March 2011. Accessed March 9, 2019.

Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097 PubMed DOI PMC

Stroup DF, Berlin JA, Morton SC, et al. . Meta-analysis of observational studies in epidemiology: a proposal for reporting: Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008-2012. doi:10.1001/jama.283.15.2008 PubMed DOI

Armand P, Kim HT, Logan BR, et al. . Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;123(23):3664-3671. doi:10.1182/blood-2014-01-552984 PubMed DOI PMC

Sorror ML, Maris MB, Storb R, et al. . Hematopoietic cell transplantation (HCT)-specific comorbidity index. Blood. 2005;106(8):2912-2919. doi:10.1182/blood-2005-05-2004 PubMed DOI PMC

Holtan SG, DeFor TE, Lazaryan A, et al. . Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood. 2015;125(8):1333-1338. doi:10.1182/blood-2014-10-609032 PubMed DOI PMC

Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GvHD-free, relapse-free survival for registry-based studies. Bone Marrow Transplant. 2016;51(4):610-611. doi:10.1038/bmt.2015.305 PubMed DOI

Sterne JAC, Hernán MA, Reeves BC, et al. . ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. doi:10.1136/bmj.i4919 PubMed DOI PMC

Guyatt GH, Oxman AD, Vist GE, et al. ; GRADE Working Group . GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-926. doi:10.1136/bmj.39489.470347.AD PubMed DOI PMC

GRADEpro McMaster University, 2015, Evidence Prime, Inc. https://gradepro.org/. Published 2015. Accessed March 20, 2019.

Gagelmann N, Kröger N. The science of evidence synthesis in hematopoietic stem-cell transplantation. Adv Cell Gene Ther. 2018;1(2):e12. doi:10.1002/acg2.12 DOI

Schwarzer G. meta: An R package for meta-analysis. R News. 2007;7(3):40-45.

Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36(3):1-48. doi:10.18637/jss.v036.i03 DOI

R Core Team The R project for Statistical Computing. https://www.R-project.org/. Accessed March 20, 2019.

Solomon SR, Sizemore CA, Sanacore M, et al. . Total body irradiation-based myeloablative haploidentical stem cell transplantation is a safe and effective alternative to unrelated donor transplantation in patients without matched sibling donors. Biol Blood Marrow Transplant. 2015;21(7):1299-1307. doi:10.1016/j.bbmt.2015.03.003 PubMed DOI

Bashey A, Zhang X, Jackson K, et al. . Comparison of outcomes of hematopoietic cell transplants from T-replete haploidentical donors using post-transplantation cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 allele-matched unrelated donors and HLA-identical sibling donors. Biol Blood Marrow Transplant. 2016;22(1):125-133. doi:10.1016/j.bbmt.2015.09.002 PubMed DOI

Rashidi A, DiPersio JF, Westervelt P, et al. . Comparison of outcomes after peripheral blood haploidentical versus matched unrelated donor allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. Biol Blood Marrow Transplant. 2016;22(9):1696-1701. doi:10.1016/j.bbmt.2016.05.010 PubMed DOI

Solh M, Zhang X, Connor K, et al. . Donor type and disease risk predict the success of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2017;23(12):2192-2198. doi:10.1016/j.bbmt.2017.08.030 PubMed DOI

Kanate AS, Mussetti A, Kharfan-Dabaja MA, et al. . Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood. 2016;127(7):938-947. doi:10.1182/blood-2015-09-671834 PubMed DOI PMC

Bashey A, Zhang X, Sizemore CA, et al. . T-cell–replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol. 2013;31(10):1310-1316. doi:10.1200/JCO.2012.44.3523 PubMed DOI

Blaise D, Fürst S, Crocchiolo R, et al. . Haploidentical T cell-replete transplantation with post-transplantation cyclophosphamide for patients in or above the sixth decade of age compared with allogeneic hematopoietic stem cell transplantation from an human leukocyte antigen-matched related or unrelated donor. Biol Blood Marrow Transplant. 2016;22(1):119-124. doi:10.1016/j.bbmt.2015.08.029 PubMed DOI

Ciurea SO, Zhang MJ, Bacigalupo AA, et al. . Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015;126(8):1033-1040. doi:10.1182/blood-2015-04-639831 PubMed DOI PMC

Al Malki MM, Yang D, Bashey A, et al. Haploidentical transplant with post-transplant cyclophosphamide versus matched unrelated donor for ALL: combined analyses from EBMT Acute Leukemia Working Group and the Haploidentical Transplant Research Consortium [abstract]. In: Proceedings of the European Society for Blood and Marrow Transplantation Annual Meeting. 2019;OS18-3.

Copelan OR, Sanikommu SR, Trivedi JS, et al. . Higher incidence of hemorrhagic cystitis following haploidentical related donor transplantation compared with matched related donor transplantation. Biol Blood Marrow Transplant. 2019;25(4):785-790. doi:10.1016/j.bbmt.2018.12.142 PubMed DOI

Martínez C, Gayoso J, Canals C, et al. ; Lymphoma Working Party of the European Group for Blood and Marrow Transplantation . Post-transplantation cyclophosphamide-based haploidentical transplantation as alternative to matched sibling or unrelated donor transplantation for Hodgkin lymphoma. J Clin Oncol. 2017;35(30):3425-3432. doi:10.1200/JCO.2017.72.6869 PubMed DOI

How J, Slade M, Vu K, et al. . T cell-replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplantation cyclophosphamide results in outcomes similar to transplantation from traditionally matched donors in active disease acute myeloid leukemia. Biol Blood Marrow Transplant. 2017;23(4):648-653. doi:10.1016/j.bbmt.2017.01.068 PubMed DOI PMC

McCurdy SR, Kasamon YL, Kanakry CG, et al. . Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. Haematologica. 2017;102(2):391-400. doi:10.3324/haematol.2016.144139 PubMed DOI PMC

Devillier R, Legrand F, Rey J, et al. . HLA-matched sibling versus unrelated versus haploidentical related donor allogeneic hematopoietic stem cell transplantation for patients aged over 60 years with acute myeloid leukemia. Biol Blood Marrow Transplant. 2018;24(7):1449-1454. doi:10.1016/j.bbmt.2018.02.002 PubMed DOI

Brissot E, Labopin M, Ehninger G, et al. . Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia. Haematologica. 2019;104(3):524-532. doi:10.3324/haematol.2017.187450 PubMed DOI PMC

Ghosh N, Karmali R, Rocha V, et al. . Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors. J Clin Oncol. 2016;34(26):3141-3149. doi:10.1200/JCO.2015.66.3476 PubMed DOI PMC

Moiseev IS, Pirogova OV, Alyanski AL, et al. . Risk-adapted GVHD prophylaxis with post-transplantation cyclophosphamide in adults after related, unrelated, and haploidentical transplantations. Eur J Haematol. 2018;100(5):395-402. doi:10.1111/ejh.13030 PubMed DOI

Pagliardini T, Harbi S, Fürst S, et al. . Post-transplantation cyclophosphamide-based haploidentical versus Atg-based unrelated donor allogeneic stem cell transplantation for patients younger than 60 years with hematological malignancies [published online November 06, 2018]. Bone Marrow Transplant. 2019;54(7):1067-1076. doi:10.1038/s41409-018-0387-y PubMed DOI

Robinson TM, Fuchs EJ, Zhang MJ, et al. ; Acute Leukemia Working Party of the European Society for Blood and Marrow Transplant and the Center for International Blood and Marrow Transplant Research . Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch? Blood Adv. 2018;2(11):1180-1186. doi:10.1182/bloodadvances.2018018291 PubMed DOI PMC

Dreger P, Sureda A, Ahn KW, et al. . PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. Blood Adv. 2019;3(3):360-369. doi:10.1182/bloodadvances.2018027748 PubMed DOI PMC

Robin M, Porcher R, Ruggeri A, et al. . HLA-mismatched donors in patients with myelodysplastic syndrome. Biol Blood Marrow Transplant. 2019;25(1):114-120. doi:10.1016/j.bbmt.2018.08.026 PubMed DOI

Di Stasi A, Milton DR, Poon LM, et al. . Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. Biol Blood Marrow Transplant. 2014;20(12):1975-1981. doi:10.1016/j.bbmt.2014.08.013 PubMed DOI PMC

Rashidi A, Hamadani M, Zhang MJ, et al. . Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. Blood Adv. 2019;3(12):1826-1836. doi:10.1182/bloodadvances.2019000050 PubMed DOI PMC

Ahmed S, Kanakry JA, Ahn KW, et al. . Lower graft-versus-host disease and relapse risk in post-transplant cyclophosphamide-based haploidentical versus matched sibling donor reduced-intensity conditioning transplant for Hodgkin lymphoma [published online May 25, 2019]. Biol Blood Marrow Transplant. 2019;S1083-8791(19)30336-2. doi:10.1016/j.bbmt.2019.05.025 PubMed DOI PMC

Gopcsa L, Andrikovics H, Barta A, et al. Comparison of outcomes after HLA-haploidentical related versus unrelated hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for acute leukemia [abstract]. In: Proceedings of the European Society for Blood and Marrow Transplantation Annual Meeting. 2019;B025.

Saini NY, Saliba RM, Rondon G, et al. . Impact of donor type and melphalan dose on allogeneic transplantation outcomes for patients with lymphoma. Biol Blood Marrow Transplant. 2019;25(7):1340-1346. doi:10.1016/j.bbmt.2019.02.002 PubMed DOI PMC

Battipaglia G, Boumendil A, Labopin M, et al. . Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia [published online February 04, 2019]. Bone Marrow Transplant. 2019. doi:10.1038/s41409-019-0459-7 PubMed DOI

Sugita J, Atsuta Y, Kurata M, et al. . Comparable survival outcomes of haploidentical stem cell transplantation and unrelated bone marrow transplantation. Blood. 2018;132:4644. PubMed

Gauthier J, Poiré X, Gac AC, et al. . Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin’s lymphoma undergoing allogeneic haematopoietic cell transplantation. Bone Marrow Transplant. 2018;53(4):400-409. doi:10.1038/s41409-017-0018-z PubMed DOI

Raiola AM, Dominietto A, di Grazia C, et al. . Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. Biol Blood Marrow Transplant. 2014;20(10):1573-1579. doi:10.1016/j.bbmt.2014.05.029 PubMed DOI

Lee CJ, Savani BN, Mohty M, et al. . Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia. Haematologica. 2017;102(11):1810-1822. doi:10.3324/haematol.2017.176107 PubMed DOI PMC

Ciurea SO, Al Malki MM, Kongtim P, et al. . The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation [published online March 04, 2019]. Bone Marrow Transplant. 2019. doi:10.1038/s41409-019-0499-z PubMed DOI

Kanakry CG, Fuchs EJ, Luznik L. Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol. 2016;13(1):10-24. doi:10.1038/nrclinonc.2015.128 PubMed DOI PMC

Kanakry CG, Bolaños-Meade J, Kasamon YL, et al. . Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide. Blood. 2017;129(10):1389-1393. doi:10.1182/blood-2016-09-737825 PubMed DOI PMC

McCurdy SR, Kanakry CG, Tsai HL, et al. . Grade II acute graft-versus-host disease and higher nucleated cell graft dose improve progression-free survival after HLA-haploidentical transplant with post-transplant cyclophosphamide. Biol Blood Marrow Transplant. 2018;24(2):343-352. doi:10.1016/j.bbmt.2017.10.023 PubMed DOI PMC

Kanakry JA, Kasamon YL, Bolaños-Meade J, et al. . Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant. 2013;19(10):1514-1517. doi:10.1016/j.bbmt.2013.07.013 PubMed DOI PMC

Crocchiolo R, Bramanti S, Vai A, et al. . Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis. Transpl Infect Dis. 2015;17(2):242-249. doi:10.1111/tid.12365 PubMed DOI PMC

Tischer J, Engel N, Fritsch S, et al. . Virus infection in HLA-haploidentical hematopoietic stem cell transplantation. Ann Hematol. 2015;94(10):1677-1688. doi:10.1007/s00277-015-2423-y PubMed DOI

Wachsmuth LP, Patterson MT, Eckhaus MA, Venzon DJ, Gress RE, Kanakry CG. Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression. J Clin Invest. 2019;130:2357-2373. doi:10.1172/JCI124218 PubMed DOI PMC

Kanakry CG, Ganguly S, Zahurak M, et al. . Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med. 2013;5(211):211ra157. doi:10.1126/scitranslmed.3006960 PubMed DOI PMC

Mielcarek M, Furlong T, O’Donnell PV, et al. . Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. Blood. 2016;127(11):1502-1508. doi:10.1182/blood-2015-10-672071 PubMed DOI PMC

Kanakry CG, O’Donnell PV, Furlong T, et al. . Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol. 2014;32(31):3497-3505. doi:10.1200/JCO.2013.54.0625 PubMed DOI PMC

McCurdy SR, Kanakry CG, Tsai HL, et al. . Development of grade II acute graft-versus-host disease is associated with improved survival after myeloablative HLA-matched bone marrow transplantation using single-agent post-transplant cyclophosphamide. Biol Blood Marrow Transplant. 2019;25(6):1128-1135. doi:10.1016/j.bbmt.2018.12.767 PubMed DOI PMC

Fuchs EJ. Related haploidentical donors are a better choice than matched unrelated donors: point. Blood Adv. 2017;1(6):397-400. doi:10.1182/bloodadvances.2016002196 PubMed DOI PMC

Marks DI, Wang T, Pérez WS, et al. . The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome–negative acute lymphoblastic leukemia in first and second complete remission. Blood. 2010;116(3):366-374. doi:10.1182/blood-2010-01-264077 PubMed DOI PMC

Scott BL, Pasquini MC, Logan BR, et al. . Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2017;35(11):1154-1161. doi:10.1200/JCO.2016.70.7091 PubMed DOI PMC

Kröger N, Iacobelli S, Franke GN, et al. . Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome. J Clin Oncol. 2017;35(19):2157-2164. doi:10.1200/JCO.2016.70.7349 PubMed DOI

Bacher U, Klyuchnikov E, Le-Rademacher J, et al. ; Lymphoma Working Committee of the CIBMTR . Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? Blood. 2012;120(20):4256-4262. doi:10.1182/blood-2012-06-436725 PubMed DOI PMC

Hamadani M, Saber W, Ahn KW, et al. . Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. Biol Blood Marrow Transplant. 2013;19(5):746-753. doi:10.1016/j.bbmt.2013.01.024 PubMed DOI PMC

Burroughs LM, O’Donnell PV, Sandmaier BM, et al. . Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14(11):1279-1287. doi:10.1016/j.bbmt.2008.08.014 PubMed DOI PMC

Post-transplant cyclophosphamide separates graft-versus host disease and graft versus leukemia effects after HLA-matched stem-cell transplantation for acute myeloid leukemia

Prediction of Nonrelapse Mortality in Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Receiving Allogeneic Stem Cell Transplantation With Posttransplantation Cyclophosphamide-based Graft Versus Host Disease Prophylaxis